TMDX
TransMedics Group Inc
NASDAQ: TMDX · HEALTHCARE · MEDICAL DEVICES
$64.30
-2.72% today
Updated 2026-06-05
Market cap
$2.55B
P/E ratio
16.89
P/S ratio
4.22x
EPS (TTM)
$4.37
Dividend yield
—
52W range
$60 – $156
Volume
1.5M
WallStSmart proprietary scores
50
out of 100
Grade: C
Hold
Investment rating
6.7
Growth
B6.5
Quality
B8.0
Profitability
A7.7
Valuation
B+5/9
Piotroski F-Score
Moderate
1.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →205 stocks currently score above 75
Price targets
Analyst target
$117.33
+82.47%
12-Month target
$121.88
+89.55%
Intrinsic (DCF)
$287.77
Margin of safety
+53.68%
2 Strong Buy6 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 27.00% — above average
+ ROE 34.80% — strong efficiency
+ Revenue growth 21.20% QoQ
+ 53.68% below intrinsic value
Risks
- Altman Z 1.67 — distress zone
- Negative free cash flow $-12.12M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $93.46M | $241.62M | $441.54M | $605.49M | $635.89M |
| Net income | $-36.23M | $-25.03M | $35.46M | $190.29M | $7.32M |
| EPS | — | — | — | — | $4.37 |
| Free cash flow | $-57.72M | $-192.09M | $-80.94M | $133.59M | $-12.12M |
| Profit margin | -38.77% | -10.36% | 8.03% | 31.43% | 27.00% |
Peer comparison
Smart narrative
TransMedics Group Inc trades at $64.30. representing a P/E of 16.89x trailing earnings. Our Smart Value Score of 50/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 1.67, it sits in the distress. TTM revenue stands at $635.89M. with profit margins at 27.00%. Our DCF model estimates intrinsic value at $287.77.
Frequently asked questions
What is TransMedics Group Inc's stock price?
TransMedics Group Inc (TMDX) trades at $64.30, on a P/E of 16.9x and a P/S of 4.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is TransMedics Group Inc overvalued?
TransMedics Group Inc carries a Smart Value Score of 50/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $287.77 versus the $64.30 price, a 53.7% margin of safety on a cash flow basis.
What is the price target of TransMedics Group Inc (TMDX)?
The 12-month analyst consensus target is $117.33, about 82.5% above the current $64.30. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of TransMedics Group Inc (TMDX)?
Our DCF model estimates intrinsic value at $287.77, a +53.7% margin of safety versus today's $64.30. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is TransMedics Group Inc's revenue?
TransMedics Group Inc's trailing twelve-month revenue is $635.89M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
TransMedics Group Inc's Altman Z-Score is 1.67, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.22x
ROE34.80%
Beta1.88
50D MA$83.70
200D MA$114.89
Shares out0.03B
Float0.03B
Short ratio—
Avg volume1.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—